MCID: HLC007
MIFTS: 61

Helicobacter Pylori Infection

Categories: Gastrointestinal diseases, Genetic diseases

Aliases & Classifications for Helicobacter Pylori Infection

MalaCards integrated aliases for Helicobacter Pylori Infection:

Name: Helicobacter Pylori Infection 57 72
Helicobacter Pylori Infection, Susceptibility to 57 29 6 40
H. Pylori Infection, Susceptibility to 57 13
Helicobacter Pylori Infections 43
H. Pylori Infection 57

Characteristics:

OMIM:

57
Inheritance:
not determined


Classifications:



External Ids:

OMIM 57 600263
MedGen 42 C1838332
UMLS 72 C0850666

Summaries for Helicobacter Pylori Infection

MedlinePlus : 43 Helicobacter pylori (H. pylori) is a type of bacteria that causes infection in the stomach. It is the main cause of peptic ulcers, and it can also cause gastritis and stomach cancer. About 30 to 40 percent of people in the United States get an H. pylori infection. Most people get it as a child. H. pylori usually does not cause symptoms. But it can break down the inner protective coating in some people's stomachs and cause inflammation. This can lead to gastritis or a peptic ulcer. Researchers aren't sure how H. pylori spreads. They think that it may spread by unclean food and water, or through contact with an infected person's saliva and other body fluids. A peptic ulcer causes a dull or burning pain in your stomach, especially when you have an empty stomach. It lasts for minutes to hours, and it may come and go for several days or weeks. It may also cause other symptoms, such as bloating, nausea, and weight loss. If you have the symptoms of a peptic ulcer, your health care provider will check to see whether you have H. pylori. There are blood, breath, and stool tests to check for H. pylori. In some cases, you may need an upper endoscopy, often with a biopsy. If you do have a peptic ulcer, the treatment is with a combination of antibiotics and acid-reducing medicines. You will need to be tested again after treatment to make sure the infection is gone. There is no vaccine for H. pylori. Since H. pylori might spread through unclean food and water, you might be able to prevent it if you Wash your hands after using the bathroom and before eating Eat properly prepared food Drink water from a clean, safe source NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Helicobacter Pylori Infection, also known as helicobacter pylori infection, susceptibility to, is related to peptic ulcer disease and atrophic gastritis, and has symptoms including nausea and vomiting, constipation and fever. An important gene associated with Helicobacter Pylori Infection is IFNGR1 (Interferon Gamma Receptor 1), and among its related pathways/superpathways are Signaling by GPCR and ERK Signaling. The drugs Acetylcysteine and Histamine have been mentioned in the context of this disorder. Affiliated tissues include testes, colon and liver, and related phenotypes are helicobacter pylori infection and Synthetic lethal with MLN4924 (a NAE inhibitor)

OMIM : 57 Helicobacter pylori is a microaerophilic, gram-negative bacterium that colonizes the gastric mucosa of approximately 50% of the world's population, and is a primary pathogenic factor in benign and malignant gastroduodenal disease (Warren and Marshall, 1983; Blaser and Parsonnet, 1994). Tomb et al. (1997) reported the complete sequence of the circular genome of H. pylori. The 1,667,867-bp genome contains 1,590 predicted coding sequences (genes). Sequence analysis of these genes indicated that the organism has systems for motility, for scavenging iron, and for DNA restriction and modification. Its survival in acid conditions depends, in part, on its ability to establish a positive inside-membrane potential in low pH. (600263)

Related Diseases for Helicobacter Pylori Infection

Diseases related to Helicobacter Pylori Infection via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 582)
# Related Disease Score Top Affiliating Genes
1 peptic ulcer disease 33.3 S100A8 IL1B GAST CYP2C19 CXCL8
2 atrophic gastritis 32.3 S100A8 IL1B GAST CXCL8
3 gastric ulcer 32.3 IL1B GAST CYP2C19 CXCL8
4 esophagitis 32.2 IL1B CYP2C19 CXCL8
5 duodenal ulcer 32.1 S100A8 IL1B GAST CYP2C19 CXCL8
6 gastritis 32.0 S100A8 MUC6 IL1B GAST CXCL8 CXCL1
7 peptic esophagitis 32.0 IL1B CYP2C19 CXCL8
8 gastroesophageal reflux 32.0 IL1B GAST CYP2C19 CXCL8
9 gastric cancer 31.3 S100A8 MUC6 MET JUN IL1B GAST
10 gastrointestinal system disease 31.1 S100A8 IL1B GAST EGFR CXCL8 CASP3
11 proteasome-associated autoinflammatory syndrome 1 31.0 IL1B CXCL8 CCL5
12 mycobacterium fortuitum 30.9 IFNGR1 CXCL8
13 intestinal disease 30.8 IL1B EGFR CXCL8 CASP3
14 idiopathic neutropenia 30.4 IL1B CCL5 CASP3
15 lung disease 30.0 IL1B EGFR CXCL8 CCL5
16 gastric adenocarcinoma 30.0 S100A8 MET JUN IL1B GAST EGFR
17 stomach disease 29.8 S100A8 MUC6 MET IL1B GAST EGFR
18 monocytic leukemia 29.7 JUN IL1B CXCL8 CASP3
19 pneumonia 29.6 IL1B CXCL8 CXCL1 CCL5
20 respiratory system disease 29.5 IL1B EGFR CXCL8 CCL5 CASP3
21 squamous cell carcinoma, head and neck 29.5 MET EGFR CXCL8 CASP3
22 rheumatoid arthritis 28.9 JUN IL1B CXCL8 CXCL1 CCL5
23 large intestine cancer 28.2 PTPN11 MET JUN IL1B GAST EGFR
24 gastric cancer, hereditary diffuse 11.9
25 dyspepsia 11.3
26 gastrointestinal ulceration, recurrent, with dysfunctional platelets 11.1
27 iron metabolism disease 11.0
28 lymphoma, mucosa-associated lymphoid type 11.0
29 deficiency anemia 10.9
30 purpura 10.9
31 adenocarcinoma 10.9
32 iron deficiency anemia 10.9
33 nodal marginal zone lymphoma 10.9
34 duodenitis 10.8
35 gastric lymphoma 10.8
36 thrombocytopenic purpura, autoimmune 10.8
37 lymphoma 10.8
38 urticaria 10.8
39 bacterial infectious disease 10.8
40 barrett esophagus 10.8
41 microinvasive gastric cancer 10.8
42 liver cirrhosis 10.8
43 diarrhea 10.8
44 coronary heart disease 1 10.7
45 liver disease 10.7
46 b-cell lymphoma 10.7
47 cytokine deficiency 10.7
48 inflammatory bowel disease 10.7
49 cholera 10.7
50 fatty liver disease 10.7

Graphical network of the top 20 diseases related to Helicobacter Pylori Infection:



Diseases related to Helicobacter Pylori Infection

Symptoms & Phenotypes for Helicobacter Pylori Infection

Human phenotypes related to Helicobacter Pylori Infection:

32
# Description HPO Frequency HPO Source Accession
1 helicobacter pylori infection 32 HP:0005202

Symptoms via clinical synopsis from OMIM:

57
G I:
helicobacter pylori infection susceptibility

Clinical features from OMIM:

600263

UMLS symptoms related to Helicobacter Pylori Infection:


nausea and vomiting, constipation, fever, abdominal pain, pruritus, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas

GenomeRNAi Phenotypes related to Helicobacter Pylori Infection according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.83 CASP3 CHUK CXCL8 IL1B JUN NFKB1
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.83 CASP3 CHUK CXCL8 IL1B JUN NFKB1

MGI Mouse Phenotypes related to Helicobacter Pylori Infection:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 10.31 ADAM10 CASP3 CCL5 CHUK EGFR GAST
2 cellular MP:0005384 10.29 ADAM10 CASP3 CHUK EGFR IFNGR1 JUN
3 hematopoietic system MP:0005397 10.29 ADAM10 CASP3 CCL5 CHUK EGFR IFNGR1
4 homeostasis/metabolism MP:0005376 10.27 ADAM10 CASP3 CHUK EGFR GAST IFNGR1
5 cardiovascular system MP:0005385 10.26 ADAM10 CASP3 CHUK EGFR IFNGR1 IL1B
6 endocrine/exocrine gland MP:0005379 10.24 ADAM10 CASP3 CHUK EGFR GAST IFNGR1
7 digestive/alimentary MP:0005381 10.18 ADAM10 CASP3 CHUK EGFR GAST IFNGR1
8 craniofacial MP:0005382 10.14 ADAM10 CASP3 CHUK EGFR IL1B MET
9 mortality/aging MP:0010768 10.13 ADAM10 CASP3 CHUK EGFR GAST IFNGR1
10 embryo MP:0005380 10.11 ADAM10 CHUK EGFR IFNGR1 JUN MET
11 integument MP:0010771 10.1 ADAM10 CASP3 CHUK EGFR IFNGR1 IL1B
12 liver/biliary system MP:0005370 9.91 CHUK EGFR IFNGR1 JUN MET NFKB1
13 nervous system MP:0003631 9.9 ADAM10 CASP3 CHUK EGFR IFNGR1 IL1B
14 neoplasm MP:0002006 9.8 CHUK EGFR GAST IFNGR1 IL1B MET
15 respiratory system MP:0005388 9.56 CASP3 CHUK EGFR JUN MET NFKB1
16 skeleton MP:0005390 9.32 ADAM10 CASP3 CHUK EGFR IFNGR1 IL1B

Drugs & Therapeutics for Helicobacter Pylori Infection

Drugs for Helicobacter Pylori Infection (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 188)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
2
Histamine Approved, Investigational Phase 4 51-45-6 774
3
Titanium dioxide Approved Phase 4 13463-67-7
4
Famotidine Approved Phase 4 76824-35-6 3325
5
Coal tar Approved Phase 4 8007-45-2
6
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
7
Sodium citrate Approved, Investigational Phase 4 68-04-2
8
Potassium Citrate Approved, Investigational, Vet_approved Phase 4
9
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
10
Loperamide Approved Phase 4 53179-11-6 3955
11
Bismuth subsalicylate Approved, Vet_approved Phase 4 14882-18-9 53629521
12
Tinidazole Approved, Investigational Phase 4 19387-91-8 5479
13
Azithromycin Approved Phase 4 83905-01-5 447043 55185
14
Ofloxacin Approved Phase 4 82419-36-1 4583
15
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
16
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
17
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
18
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
19
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
20
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 4 303-98-0 5281915
21
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
22
Sulforaphane Investigational Phase 4 4478-93-7, 142825-10-3 5350
23
Furazolidone Experimental, Vet_approved Phase 4 67-45-8 3435 5323714
24 N-monoacetylcystine Phase 4
25 Antidotes Phase 4
26 Free Radical Scavengers Phase 4
27 Antioxidants Phase 4
28 Antiviral Agents Phase 4
29
Histamine Phosphate Phase 4 51-74-1 65513
30 Histamine Antagonists Phase 4
31 Histamine H2 Antagonists Phase 4
32 Acidophilus Phase 4
33 Dermatologic Agents Phase 4
34 Photosensitizing Agents Phase 4
35 Sunscreening Agents Phase 4
36 Radiation-Protective Agents Phase 4
37 Hemostatics Phase 4
38 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
39 Citrate Phase 4
40 Respiratory System Agents Phase 4
41 Natriuretic Agents Phase 4
42 diuretics Phase 4
43 Chelating Agents Phase 4
44 Expectorants Phase 4
45 Anticoagulants Phase 4
46 Calcium, Dietary Phase 4
47 Neurotransmitter Agents Phase 4
48 Bifidobacterium Phase 4
49 Micronutrients Phase 4
50 Trace Elements Phase 4

Interventional clinical trials:

(show top 50) (show all 372)
# Name Status NCT ID Phase Drugs
1 Tailored Therapy Versus Standard Triple Therapy for Helicobacter Pylori Eradication in Children: A Randomized Trial Unknown status NCT02635191 Phase 4 Tailored Group;Standard group
2 Optimal Duration of Antimicrobial Susceptibility Test (AST) Guided Rescue Therapy for Helicobacter Pylori Infection Unknown status NCT02934048 Phase 4
3 Comparison of the Efficacy of Clarithromycin-based Triple Therapy Versus Quadruple Therapies in the First Line Therapy of Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial Unknown status NCT01906879 Phase 4 triple, quadruple, non-bismuth quadruple therapy
4 Helicobacter Pylori Eradication Rates of Concomitant Therapy and Tailored Therapy Based on 23S Ribosomal RNA Point Mutations Associated With Clarithromycin Resistance: A Multicenter Prospective Randomized Study Unknown status NCT03130452 Phase 4 Lansoprazole 30mg;Amoxicillin 1.0g Tab;Clarithromycin 500mg;Metronidazole 500 mg
5 Comparison of the Efficacy of Triple Therapy With or Without Acetylcysteine in the First Line of Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial Unknown status NCT02249546 Phase 4 N-acetylcysteine + PPI-amoxicillin-clarithromycin;PPI-amoxicillin-clarithromycin
6 Efficacy of 10-day Concomitant Regimen Versus High Dose Dual Therapy in Anti-Helicobacter Pylori Rescue Therapy Unknown status NCT01265069 Phase 4 high dose dual therapy;concomitant therapy
7 Helicobacter Pylori Eradication Using a Bismuth Quadruple Therapy Among Asymptomatically Infected Adults in El Paso, Texas: A Pilot Study. Unknown status NCT01335334 Phase 4 bismuth subcitrate potassium, metronidazole,tetracycline hydrochloride and omeprazole
8 Phase 4, Prospective, Randomized Study Comparing 14-day Non-bismuth Quadruple "Hybrid" and "Concomitant" Therapies for Helicobacter Pylori Eradication in Settings With High Clarithromycin Resistance Unknown status NCT01464060 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
9 Comparison of Triple Therapy Regimens Effectiveness Over 10 Days and 14 Days in Eradication of Helicobacter Pylori Infection: Double Blind Randomized Clinical Trial Unknown status NCT03134378 Phase 4 Rabeprazole Sodium 20mg;Clarithromycin 500mg;Amoxicillin 500 Mg
10 Comparison of the Eradications Rates of Sequential Therapy Versus Concomitant Therapy of Treatment of Helicobacter Pylori Infection in Korea Unknown status NCT02108184 Phase 4 Sequential therapy 10 days;Sequential therapy 14 days;Concomitant therapy 10 days;Concomitant therapy 14 days
11 Food Effect on the Eradication Rate of H. Pylori With Triple Therapy With Esomeprazole Unknown status NCT02552641 Phase 4 Esomeprazole;Amoxicillin;Clarythromycin
12 Comparison of the Efficacy of Clarithromycin-based Triple Therapy for 14 Days Versus Sequential Therapy for 10 Days in the First Line Therapy for Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial Unknown status NCT01607918 Phase 4 D1-D5: (lansoprazole + amoxicillin ) D6-D10: (lansoprazole+clarithromycin +metronidazole);D1-D14: (lansoprazole + clarithromycin + amoxicillin)
13 A Randomized, Double-blind, Placebo-controlled Study of the Usefulness of the Probiotic 'Lactobacillus Reuteri' in the Therapy of Quadruple Eradication of Helicobacter Pylori Infection in Usual Clinical Practice Unknown status NCT03150394 Phase 4
14 The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation (Crohn's Disease) and Markers of Inflammation Unknown status NCT01765998 Phase 4 Probiotic;Placebo
15 Antimicrobial Susceptibility Testing Guided Triple Therapy in Salvage Helicobacter Pylori Treatment Unknown status NCT03139253 Phase 4 amoxicillin;clarithromycin;tinidazole;levofloxacin;furazolidone;tetracycline;Ilaprazole
16 Efficacy of Two Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment Unknown status NCT02988089 Phase 4 Clarithromycin susceptibility dependant strategy;2 susceptible antibiotics (amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline );proton pump inhibitor (PPI) and Colloidal Bismuth Pectin;amoxicillin and clarithromycin or amoxicillin and furazolidone;amoxicillin and furazolidone or amoxicillin and tetracycline;amoxicillin and furazolidone or amoxicillin and Tinidazole or amoxicillin and Levofloxacin
17 Rabeprazole Based Sequential-Concommitant Hybrid Therapies for H. Pylori Infections Unknown status NCT01566643 Phase 4 RA5-RACM7;RA3-RACM7;RA7-RACM7
18 Increased Second-line Eradication Rate of Helicobacter Pylori by Adding N-acetylcystein or Metronidazole to the Conventional Triple Therapy. Unknown status NCT01572597 Phase 4 10RAC+acetylcystein;10RAC+metronidazole
19 Genotypic Resistance Guided Therapy in the Treatment of Helicobacter Pylori Infection Unknown status NCT01725906 Phase 4 empirical therapy;Genotypic resistance guided therapy
20 Phase 4 Study of Helicobacter Pylori Eradication Therapy Unknown status NCT00990405 Phase 4 Lansoprzole+Amoxicillin+Clarithromycin
21 Comparison of the Efficacy of Levofloxacin-based Sequential Therapy and Triple Therapy as Second Line Therapy for Refractory Helicobacter Pylori Infection- A Multi-center Randomized Trial Unknown status NCT01537055 Phase 4 levofloxacin-based sequential therapy;levofloxacin-based triple therapy for 10 days
22 Phase 4, Prospective, Randomized and Comparative Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice Unknown status NCT01273441 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
23 The Efficacy of Sequential Therapy as Second Line Therapy for Refractory Helicobacter Pylori Infection - A Pilot Study Completed NCT00885417 Phase 4 Cravit-based sequential therapy
24 Comparison Between Ten Days Sequential Treatment (With Metronidazole or Tetracycline) and Ten Days Standard Triple Therapy of Helicobacter Pylori Completed NCT01573975 Phase 4 5RA-5RCM;5RA-5RCT;10RCA
25 Comparison of Dexlansoprazole-based Triple and Rabeprazole-based Triple Therapies for Helicobacter Pylori Infection Completed NCT02541786 Phase 4 dexlansoprazole based triple therapy;rabeprazole-based triple therapy
26 The Efficacy of Susceptibility Test -Driven Sequential Therapy as the Third Line Therapy for Refractory Helicobacter Pylori Infection Completed NCT01032655 Phase 4 susceptibility test guided sequential therapy
27 Comparison of 7-day Triple, 10-day Sequential, and 7-day Concomitant Therapies for Helicobacter Pylori Infection in Taiwan Completed NCT01769365 Phase 4 7-day quadruple therapy;10-day sequential therapy;7-day standard triple therapy
28 Phase IV Study Comparing the Duration of Sequential Therapy Completed NCT01042184 Phase 4 Sequential therapy for 14 days;Sequential therapy for 10 days;Triple therapy for 14 days
29 Intraluminal Therapy for Helicobacter Pylori Infection Completed NCT03124420 Phase 4 Lansoprazole;Amoxicillin;Clarithromycin
30 Comparison of 14-day Sequential and Hybrid Therapies for H Pylori Infection Completed NCT01085786 Phase 4 14-day sequential treatment;14-day hybrid treatment
31 Efficacy of High-dose Dual Therapy Versus Bismuth-containing Quadruple Therapy for First-line Treatment of Helicobacter Pylori Infection - A Prospective, Randomized, Comparative Study Completed NCT02483715 Phase 4 High-dose dual therapy (rabeprazole, amoxicillin);Bismuth-containing quadruple therapy (rabeprazole, tripotassium dicitrate bismuthate, metronidazole, tetracycline)
32 A Greek, Single Center, Randomized, Double Blind Controlled Clinical Study Comparing the 10-day Versus the 14-day Concomitant Proton Pump Inhibitor [PPI] + Amoxicillin + Metronidazole + Clarithromycin (PAMC) Therapeutic Scheme as First-line Treatment Strategy for the Eradication of H. Pylori Infection Completed NCT02959255 Phase 4 Esomeprazole
33 Prospective, Randomized Controlled Trial Comparing High Dose Amoxicillin Versus Tetracycline Based Quadruple Therapy as Second-line Treatment for Resistant Helicobacter Pylori Infection Completed NCT02175927 Phase 4 Lansoprazole;Bismuth Potassium Citrate;Metronidazole;Amoxicillin;Tetracycline
34 Visiting Staff, Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan Completed NCT03524833 Phase 4 Metronidazole;Lansoprazole, Amoxicillin, Metronidazole
35 Visiting Staff, Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan Completed NCT03521726 Phase 4 Amoxicillin;Rabeprazole, Amoxicillin
36 Visiting Staff, Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan Completed NCT03516669 Phase 4 Clarithromycin;Amoxicillin, Clarithromycin
37 Adding Bismuth to Rabeprazole-based First-line Triple Therapy Does Not Improve the Eradication of Helicobacter Pylori Completed NCT03108287 Phase 4 RAK therapy;RBAK therapy
38 Comparison of Daily Single Dose Triple and Conventional Triple Therapies for Helicobacter Pylori Infection Completed NCT02711176 Phase 4 Nexium;Tinafas;Tavanex;Lanzol;Klacid;Iramox
39 An Interventional, Prospective, Multi-center, Double-blind, Placebo Controlled Postmarketing Study to Evaluate Efficacy and Safety of Normia® Probiotic Treatment as a Supportive Therapy in Eradication of H. Pylori Completed NCT01969331 Phase 4
40 The Effect of High Dose Citric on PPI (Proton Pump Inhibitors)Induced False Negative H. Pylori UBT Rates Completed NCT00825630 Phase 4 Lansoprazole (Lanton);Omeprezole (Losec);Pantoprazole(Controloc);Esomeprazole (Nexium)
41 Levofloxacin and Bismuth-containing Therapy Versus Quadruple Therapy as Second-line Treatment of Resistant Helicobacter Pylori Infection Completed NCT01742429 Phase 4 Proton pump inhibitor;Bismuth subsalicylate;Metronidazole;Tetracycline;Amoxicillin;Levofloxacin
42 Comparison Between Hybrid, Reverse Hybrid, and Non-Bismuth Levofloxacin Quadruple Regimens for Helicobacter Pylori Infection in Egypt: A Randomized Controlled Trial Completed NCT04039412 Phase 4 Hybrid regimen;Reverse hybrid regimen;Levofloxacin quadruple regimen
43 A Randomized Controlled Trial of Triple Therapy Versus Sequential Therapy Versus Concomitant Therapy as First Line Treatment for Helicobacter Pylori Infection Completed NCT02092506 Phase 4 10 day triple therapy;10 day sequential therapy;10 day concomitant therapy
44 Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura Completed NCT00467571 Phase 4 lansoprazole, clarithromycin, amoxycillin
45 Relation of Metabolic Rate of Omeprazole and Eradication of Helicobacter Pylori Infection - A Combination of Clinical and Pharmacogenetic Study Completed NCT00854451 Phase 4 omeprazole plus amoxicillin;omeprazole plus amoxicillin;omeprazole plus amoxicillin;omeprazole plus amoxicillin
46 Efficacy of High Dose of Amoxicillin And Metronidazole Plus Bismuth For Helicobacter Pylori Treatment In Naive Patients : A Randomized Clinical Trial Completed NCT03557437 Phase 4 Esomeprazole;Amoxicillin, Metronidazole;Bismuth Potassium Citrate
47 Efficacy of Antibiotic Susceptibility-based Tailored Versus Empiric Therapy for Helicobacter Pylori First-line Treatment:a Randomized Clinical Trial Completed NCT02935010 Phase 4 Esomeprazole;Bismuth Potassium Citrate;Amoxicillin;Clarithromycin;Metronidazole;Levofloxacin
48 Efficacy of Tailored for Helicobacter Pylori Rescue Treatment Based on Antimicrobial-susceptibility Testing Completed NCT03413020 Phase 4 esomeprazole;bismuth Potassium Citrate;amoxicillin;clarithromycin;metronidazole;levofloxacin
49 A Randomized Clinical Trial of Clarithromycin/Bismuth Containing Quadruple Therapy for Helicobacter Pylori First-line Treatment Completed NCT02732249 Phase 4 Esomeprazole;Bismuth Potassium Citrate;Clarithromycin;Metronidazole
50 Once Daily Dose Dexlansoprazole Levofloxacin Based Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Controlled Study Completed NCT03087162 Phase 4 Dexlansoprazole 60 mg once daily

Search NIH Clinical Center for Helicobacter Pylori Infection

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Bismuth subcitrate potassium
Bismuth subsalicylate
Esomeprazole
Famotidine
Lansoprazole
Metronidazole
Nizatidine
Omeprazole
Pantoprazole
Rabeprazole
Tetracycline
Urea C-13
Urea C-14

Genetic Tests for Helicobacter Pylori Infection

Genetic tests related to Helicobacter Pylori Infection:

# Genetic test Affiliating Genes
1 Helicobacter Pylori Infection, Susceptibility to 29 IFNGR1

Anatomical Context for Helicobacter Pylori Infection

MalaCards organs/tissues related to Helicobacter Pylori Infection:

41
Testes, Colon, Liver, T Cells, B Cells, Heart, Kidney

Publications for Helicobacter Pylori Infection

Articles related to Helicobacter Pylori Infection:

(show top 50) (show all 12191)
# Title Authors PMID Year
1
Genomewide linkage analysis identifies polymorphism in the human interferon-gamma receptor affecting Helicobacter pylori infection. 38 8 71
12516030 2003
2
Natural antibiotic function of a human gastric mucin against Helicobacter pylori infection. 38 8
15310903 2004
3
Transmission of Helicobacter pylori infection. 38 8
7672655 1995
4
Expression of a human alpha-1,3/4-fucosyltransferase in the pit cell lineage of FVB/N mouse stomach results in production of Leb-containing glycoconjugates: a potential transgenic mouse model for studying Helicobacter pylori infection. 38 8
7878011 1995
5
Helicobacter pylori infection: genetic and environmental influences. A study of twins. 38 8
8185146 1994
6
Seroprevalence of helicobacter pylori infection in couples. 38 8
2037687 1991
7
Efficacy and safety of eradication therapy for elderly patients with helicobacter pylori infection. 38 17
31348311 2019
8
A genome-wide association study identifies two susceptibility loci for duodenal ulcer in the Japanese population. 8
22387998 2012
9
A regulatory polymorphism in interferon-gamma receptor 1 promoter is associated with the susceptibility to chronic hepatitis B virus infection. 71
19488747 2009
10
Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. 8
18488030 2008
11
Helicobacter exploits integrin for type IV secretion and kinase activation. 8
17943123 2007
12
Polymorphism within the interferon-gamma/receptor complex is associated with pulmonary tuberculosis. 71
16690980 2006
13
Distinguishing human ethnic groups by means of sequences from Helicobacter pylori: lessons from Ladakh. 8
15051885 2004
14
Protective immunity against Helicobacter is characterized by a unique transcriptional signature. 8
14528007 2003
15
Treatment of Helicobacter gastritis with IL-4 requires somatostatin. 8
14555768 2003
16
Mice deficient in protein tyrosine phosphatase receptor type Z are resistant to gastric ulcer induction by VacA of Helicobacter pylori. 8
12598897 2003
17
Lewis enzyme (alpha1-3/4 fucosyltransferase) polymorphisms do not explain the Lewis phenotype in the gastric mucosa of a Portuguese population. 8
12730721 2003
18
Helicobacter pylori and gastrointestinal tract adenocarcinomas. 8
11902583 2002
19
Polymorphisms of two fucosyltransferase genes (Lewis and Secretor genes) involving type I Lewis antigens are associated with the presence of anti-Helicobacter pylori IgG antibody. 8
11535550 2001
20
The complete genome sequence of the gastric pathogen Helicobacter pylori. 8
9252185 1997
21
Parasitism by the "slow" bacterium Helicobacter pylori leads to altered gastric homeostasis and neoplasia. 8
8040281 1994
22
Gene structure of the Helicobacter pylori cytotoxin and evidence of its key role in gastric disease. 8
8163943 1994
23
Attachment of Helicobacter pylori to human gastric epithelium mediated by blood group antigens. 8
8018146 1993
24
Purification and characterization of the vacuolating toxin from Helicobacter pylori. 8
1587837 1992
25
Unidentified curved bacilli on gastric epithelium in active chronic gastritis. 8
6134060 1983
26
A meta-analysis of the association between the presence of Helicobacter pylori and periodontal diseases. 17
31145357 2019
27
The effect of early Helicobacter pylori eradication on the healing of ESD-induced artificial ulcers: A retrospective study. 17
31145312 2019
28
Evaluating Diagnostic Tests for Helicobacter pylori Infection Without a Reference Standard: Use of Latent Class Analysis. 38
31432642 2020
29
Helicobacter pylori infection and the risk of colorectal carcinoma: a systematic review and meta-analysis. 38
31368293 2019
30
Suicide journey of H. pylori through gastric carcinogenesis: the role of non-H. pylori microbiome and potential consequences for clinical practice. 38
31114971 2019
31
Gastric cancer: epidemiology, biology, and prevention: a mini review. 38
31386635 2019
32
Time trends in the incidence of esophageal adenocarcinoma, gastric adenocarcinoma, and superficial esophagogastric junction adenocarcinoma. 38
30927083 2019
33
Smoking and Helicobacter pylori infection: an individual participant pooled analysis (Stomach Cancer Pooling- StoP Project). 38
30272597 2019
34
Helicobacter pylori Infection: One More Contributor to Nonalcoholic Fatty Liver Disease Pathophysiology. 38
31033804 2019
35
Is breath testing without 13C-labelled external urea able to detect Helicobacter pylori infection? 38
31201459 2019
36
Single-nucleotide polymorphisms in Toll-like receptor genes are associated with the prognosis of gastric cancer and are not associated with Helicobacter pylori infection. 38
31173934 2019
37
VacA generates a protective intracellular reservoir for Helicobacter pylori that is eliminated by activation of the lysosomal calcium channel TRPML1. 38
31110360 2019
38
Helicobacter pylori pathogenicity and primary antimicrobial resistance in Northern Spain. 38
31192451 2019
39
Treatment of Helicobacter pylori in Special Patient Populations. 38
31400244 2019
40
Helicobacter pylori infection, chronic atrophic gastritis and risk of stomach and esophagus cancer: results from the prospective population-based ESTHER cohort study. 38
31376284 2019
41
CHAC1 overexpression in human gastric parietal cells with Helicobacter pylori infection in the secretory canaliculi. 38
31111570 2019
42
Epidemiological characterization, genetic alterations of Helicobacter pylori infection in chronic gastric disorder and prognostic values of heterozygosity loss in chromosome 3p. 38
31250359 2019
43
The important role played by chemokines influence the clinical outcome of Helicobacter pylori infection. 38
31348950 2019
44
Th17 cells in Helicobacter pylori infection: A dichotomy of help and harm. 38
31427446 2019
45
No association between Helicobacter pylori infection and gastrointestinal complaints in a large cohort of symptomatic children. 38
30656740 2019
46
Lack of Association between Past Helicobacter pylori Infection and Diabetes: A Two-Cohort Study. 38
31409000 2019
47
Effect of vitamin D on Helicobacter pylori infection and eradication: A meta-analysis. 38
31411799 2019
48
Empiric Versus Resistance-Guided Therapy in Obese Patients with Helicobacter Pylori Infection. 38
31407154 2019
49
Influence of Helicobacter pylori Infection and Atrophic Gastritis on the Gut Microbiota in a Japanese Population. 38
31394526 2019
50
Association between duration of dialysis and Helicobacter pylori infection in dialysis patients: a meta-analysis. 38
31214954 2019

Variations for Helicobacter Pylori Infection

ClinVar genetic disease variations for Helicobacter Pylori Infection:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 IFNGR1 IFNGR1, -56C-T single nucleotide variant protective,risk factor

Expression for Helicobacter Pylori Infection

Search GEO for disease gene expression data for Helicobacter Pylori Infection.

Pathways for Helicobacter Pylori Infection

Pathways related to Helicobacter Pylori Infection according to GeneCards Suite gene sharing:

(show top 50) (show all 159)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.32 PTPN11 PAK1 NFKBIA NFKB1 MET JUN
2
Show member pathways
14.01 PAK1 NFKBIA NFKB1 MET JUN IL1B
3
Show member pathways
13.99 PTPN11 PAK1 NFKBIA NFKB1 MET JUN
4
Show member pathways
13.95 S100A8 PTPN11 PAK1 NOD1 NFKBIA NFKB1
5
Show member pathways
13.83 PTPN11 NFKBIA NFKB1 MUC6 MET JUN
6
Show member pathways
13.83 NFKBIA NFKB1 MET JUN IL1B IFNGR1
7
Show member pathways
13.7 PTPN11 PAK1 NFKBIA NFKB1 MET JUN
8
Show member pathways
13.57 PAK1 NFKB1 MET IL1B EGFR CXCL8
9
Show member pathways
13.53 PAK1 NFKB1 JUN EGFR CXCL8 CXCL1
10
Show member pathways
13.42 PTPN11 NOD1 NFKB1 MET IL1B IFNGR1
11
Show member pathways
13.36 PAK1 NFKBIA NFKB1 JUN IL1B IFNGR1
12
Show member pathways
13.25 PTPN11 PAK1 NFKBIA NFKB1 MET JUN
13
Show member pathways
13.21 NOD1 NFKBIA NFKB1 JUN IL1B IFNGR1
14
Show member pathways
13.17 PAK1 NFKB1 MET JUN EGFR CHUK
15
Show member pathways
13.17 PAK1 NFKBIA NFKB1 MET JUN CHUK
16
Show member pathways
13.13 PAK1 NFKBIA NFKB1 JUN EGFR CHUK
17
Show member pathways
13.1 PAK1 NFKBIA NFKB1 MET JUN EGFR
18
Show member pathways
13.06 PAK1 NFKBIA NFKB1 JUN CXCL8 CXCL1
19
Show member pathways
13.05 NFKBIA NFKB1 IL1B IFNGR1 CXCL8 CHUK
20
Show member pathways
13.04 PTPN11 NFKBIA NFKB1 JUN EGFR CHUK
21 13 NFKBIA NFKB1 MET JUN IFNGR1 EGFR
22 12.96 PAK1 NFKB1 MET JUN IL1B EGFR
23
Show member pathways
12.92 NFKBIA NFKB1 JUN CHUK CASP3
24
Show member pathways
12.92 NFKBIA NFKB1 IL1B CXCL8 CHUK CCL5
25
Show member pathways
12.9 PTPN11 PAK1 NFKBIA NFKB1 MET JUN
26
Show member pathways
12.89 PTPN11 NFKBIA NFKB1 JUN CHUK
27
Show member pathways
12.89 PTPN11 PAK1 NFKB1 MET EGFR CHUK
28
Show member pathways
12.88 PTPN11 NFKBIA NFKB1 MET EGFR CHUK
29
Show member pathways
12.88 NFKBIA NFKB1 JUN IL1B IFNGR1 EGFR
30
Show member pathways
12.86 NFKBIA NFKB1 MET IL1B EGFR CHUK
31
Show member pathways
12.86 PAK1 NFKBIA NFKB1 JUN IL1B EGFR
32
Show member pathways
12.83 PAK1 NFKBIA NFKB1 JUN IL1B IFNGR1
33
Show member pathways
12.8 PAK1 NFKBIA NFKB1 JUN IFNGR1 CHUK
34
Show member pathways
12.8 PAK1 NFKBIA NFKB1 JUN IL1B CHUK
35
Show member pathways
12.78 PTPN11 PAK1 NFKB1 MET JUN EGFR
36
Show member pathways
12.77 NFKBIA NFKB1 JUN IL1B IFNGR1 CHUK
37
Show member pathways
12.76 PTPN11 PAK1 NFKBIA NFKB1 JUN IL1B
38
Show member pathways
12.76 PTPN11 PAK1 NFKBIA NFKB1 IL1B EGFR
39 12.74 NOD1 NFKBIA NFKB1 IL1B CHUK CCL5
40
Show member pathways
12.72 PTPN11 NFKBIA NFKB1 JUN CHUK
41
Show member pathways
12.66 PTPN11 PAK1 JUN IFNGR1 CASP3
42
Show member pathways
12.63 PTPN11 PAK1 NFKBIA NFKB1 JUN CHUK
43
Show member pathways
12.62 PAK1 NFKBIA NFKB1 MUC6 IL1B CHUK
44
Show member pathways
12.6 NFKBIA NFKB1 JUN GAST EGFR CHUK
45
Show member pathways
12.6 PTPN11 PAK1 NFKBIA NFKB1 JUN IL1B
46
Show member pathways
12.59 PTPN11 PAK1 NFKBIA NFKB1 JUN CHUK
47
Show member pathways
12.58 PAK1 NFKBIA NFKB1 JUN CHUK
48
Show member pathways
12.57 PTPN11 NFKBIA NFKB1 JUN CHUK
49
Show member pathways
12.56 PAK1 MET JUN EGFR CASP3
50
Show member pathways
12.56 PTPN11 NFKBIA NFKB1 MET CHUK

GO Terms for Helicobacter Pylori Infection

Cellular components related to Helicobacter Pylori Infection according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.97 S100A8 PTPN11 PAK1 NOD1 NFKBIA NFKB1
2 extracellular region GO:0005576 9.65 S100A8 NFKB1 MUC6 MET IL1B GAST
3 I-kappaB/NF-kappaB complex GO:0033256 8.62 NFKBIA NFKB1

Biological processes related to Helicobacter Pylori Infection according to GeneCards Suite gene sharing:

(show all 47)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell migration GO:0030335 9.95 PAK1 IL1B EGFR CCL5 ADAM10
2 cellular response to lipopolysaccharide GO:0071222 9.94 NFKB1 IL1B CXCL8 CXCL1
3 chemotaxis GO:0006935 9.93 S100A8 CXCL8 CXCL1 CCL5
4 MAPK cascade GO:0000165 9.93 PAK1 MET IL1B EGFR CCL5
5 Fc-epsilon receptor signaling pathway GO:0038095 9.88 PAK1 NFKB1 JUN CHUK
6 liver development GO:0001889 9.86 MET JUN EGFR
7 positive regulation of cell growth GO:0030307 9.86 S100A8 EGFR ADAM10
8 response to organic substance GO:0010033 9.86 PAK1 JUN CHUK CASP3
9 cellular response to interleukin-1 GO:0071347 9.85 NFKB1 CXCL8 CCL5
10 positive regulation of inflammatory response GO:0050729 9.85 S100A8 NFKBIA EGFR
11 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.85 S100A8 NOD1 NFKB1 IL1B CHUK
12 chemokine-mediated signaling pathway GO:0070098 9.84 CXCL8 CXCL1 CCL5
13 cellular response to organic cyclic compound GO:0071407 9.84 IL1B CCL5 CASP3
14 positive regulation of interleukin-6 production GO:0032755 9.83 PTPN11 NOD1 IL1B
15 cellular response to tumor necrosis factor GO:0071356 9.83 NFKBIA NFKB1 CXCL8 CHUK CCL5
16 positive regulation of smooth muscle cell proliferation GO:0048661 9.82 JUN EGFR CCL5
17 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.82 NOD1 IL1B EGFR
18 cellular response to mechanical stimulus GO:0071260 9.81 PTPN11 NFKB1 IL1B EGFR
19 response to lipopolysaccharide GO:0032496 9.8 S100A8 NFKBIA JUN IL1B CHUK CASP3
20 cytokine-mediated signaling pathway GO:0019221 9.8 PTPN11 IL1B IFNGR1 CXCL8 CXCL1 CCL5
21 cellular response to cadmium ion GO:0071276 9.78 JUN EGFR CHUK
22 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.78 PAK1 NFKB1 MUC6 CHUK
23 response to organic cyclic compound GO:0014070 9.77 JUN EGFR CASP3
24 lipopolysaccharide-mediated signaling pathway GO:0031663 9.77 NFKBIA IL1B CCL5
25 neutrophil chemotaxis GO:0030593 9.77 S100A8 IL1B CXCL8 CXCL1 CCL5
26 cellular response to reactive oxygen species GO:0034614 9.76 JUN EGFR CHUK
27 response to tumor necrosis factor GO:0034612 9.74 CCL5 CASP3 ADAM10
28 wound healing GO:0042060 9.71 S100A8 PAK1 EGFR CASP3
29 negative regulation of G protein-coupled receptor signaling pathway GO:0045744 9.7 CXCL8 CCL5
30 eyelid development in camera-type eye GO:0061029 9.7 JUN EGFR
31 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.69 S100A8 NOD1
32 negative regulation by host of viral transcription GO:0043922 9.69 JUN CCL5
33 hepatocyte growth factor receptor signaling pathway GO:0048012 9.69 PAK1 MET
34 neutrophil activation GO:0042119 9.67 CXCL8 CCL5
35 response to muscle stretch GO:0035994 9.67 NFKBIA NFKB1 JUN
36 positive regulation of neuron apoptotic process GO:0043525 9.63 JUN CASP3
37 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.55 PTPN11 NOD1 JUN EGFR CCL5
38 interleukin-1-mediated signaling pathway GO:0070498 9.35 NOD1 NFKBIA NFKB1 IL1B CHUK
39 inflammatory response GO:0006954 9.23 S100A8 NOD1 NFKB1 IL1B CXCL8 CXCL1
40 signal transduction GO:0007165 10.27 NOD1 NFKB1 MET IL1B IFNGR1 GAST
41 positive regulation of transcription by RNA polymerase II GO:0045944 10.2 NFKBIA NFKB1 MET JUN IL1B EGFR
42 positive regulation of cell proliferation GO:0008284 10.1 PAK1 JUN IL1B EGFR ADAM10
43 positive regulation of transcription, DNA-templated GO:0045893 10.1 NFKBIA NFKB1 JUN IL1B EGFR CHUK
44 immune response GO:0006955 10.07 IL1B CXCL8 CXCL1 CHUK CCL5
45 apoptotic process GO:0006915 10.07 S100A8 PAK1 NOD1 NFKBIA NFKB1 IL1B
46 intracellular signal transduction GO:0035556 10.06 NOD1 EGFR CXCL8 CXCL1 CASP3
47 negative regulation of apoptotic process GO:0043066 10.01 NFKBIA NFKB1 JUN EGFR CASP3

Molecular functions related to Helicobacter Pylori Infection according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 9.8 NOD1 NFKB1 JUN CHUK CCL5 ADAM10
2 protein kinase activity GO:0004672 9.77 PAK1 MET EGFR CHUK CCL5
3 cytokine activity GO:0005125 9.56 IL1B CXCL8 CXCL1 CCL5
4 identical protein binding GO:0042802 9.5 NOD1 NFKBIA NFKB1 MET JUN EGFR
5 chemokine activity GO:0008009 8.8 CXCL8 CXCL1 CCL5
6 protein binding GO:0005515 10.09 S100A8 PTPN11 PAK1 NOD1 NFKBIA NFKB1

Sources for Helicobacter Pylori Infection

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....